ABSTRACT
Background: Positron emission tomography with computed tomography (PET/CT) has proven its value for the differential diagnosis of fever of unknown origin (FUO). However, the extent to which PET/CT during FUO evaluation can shorten the length of hospital stay (LOS) remains unclear. Materials and Methods: A retrospective review of the medical records over a 10-year period from January 2009 to December 2018 of a tertiary university hospital was performed. The inclusion criteria were symptoms with fever persisting for >3 weeks before admission, as defined in classical FUO. Medical records in which PET/CT was performed after the final diagnosis, such as neoplastic causes, were excluded. Moreover, in the neoplasm category evaluated using PET/CT, only diagnostic PET/CT cases were enrolled;PET/CT cases for confirming metastasis or staging were excluded. Final diagnoses were categorized as infection, neoplasm, noninfectious non-neoplastic inflammatory disorder, miscellaneous, and uncategorizable. Each category was separated into evaluation with and without PET/CT for statistical analyses. Results: In total, 91 patients underwent evaluation for FUO and about one in three underwent PET/CT. Overall LOS was not different between the PET/CT and non-PET/CT groups;however, there were differences in LOS within the categories. For infectious causes, the mean LOS was 21.1 and 11.1 days in the PET/CT and non-PET/CT groups, respectively (P = 0.022). For neoplastic causes, the mean LOS was 11.4 and 36.0 days in the PET/CT and non-PET/CT Conclusion: Most patients with FUO were aged 50 - 60 years, and their family and work roles were crucial. A lower LOS may benefit both the patients' families and society at large. Interestingly, PET/CT may contribute to shortening the LOS during FUO evaluation when the causes are neoplastic, by approximately 24 days.
ABSTRACT
This study explored how changes in stress, anxiety about COVID-19, and leisure participation affected individuals' well-being during the COVID-19 pandemic. The study included two waves of data collection from 454 participants aged 30–49 years in South Korea;data collection occurred during the two peaks of the pandemic in 2020. A series of analyses was used to examine the associations in leisure patterns, demographic characteristics, stress, anxiety, and well-being during the pandemic. The results indicated that the participants' leisure patterns shifted from participating in more home leisure to outdoor leisure between the two waves during the pandemic. In addition, participating in more outdoor leisure activities was found to contribute to better well-being. An improved understanding of the associations between the COVID-19 pandemic and various aspects of life is important for effective leisure development and to help people overcome life's difficulties during and after the pandemic. © 2023 National Recreation and Park Association.
ABSTRACT
Background. There are few data on immune correlation of protection from breakthrough Omicron (B.1.1.529) infection in individuals who received booster vaccines. We thus compared a neutralizing antibody titers against Omicron within the first month after the mRNA booster at the time before omicron wave between healthcare works (HCWs) who experienced Omicron breakthrough infections and HCWs without Omicron infections. Methods. We enrolled HCWs without the history of SARS-CoV-2 infection who agreed with blood sampling 2 weeks after booster vaccination at Asan Medical Center, Seoul, South Korea, between November 2021 and December 2022 (Delta dominant era). We identified breakthrough infections by performing SARS-CoV-2 RT-PCR though nasopharyngeal swab specimen in HCWs who had COVID-19-related symptoms or had known exposure to confirmed SARS-CoV-2-infected patients, between 1 February and 25 April 2022 (Omicron dominant era). SARS-CoV-2 S1-specific IgG antibody titers were measured using enzyme-linked immunosorbent assay (ELISA). Plasma levels of live-virus neutralizing antibodies were measured using a microneutralization assay with SARS-CoV-2 omicron variants. Results. Among 134 HCWs, 69 (52%) received two-dose ChAdOx1 nCoV-19 followed by BNT162b2, 50 (37%) three-dose BNT162b2, and 15 (11%) 3-dose mRNA-1273. Of them, 57 (43%) experienced breakthrough Omicron infection at median 121 days (IQR 99-147) after booster vaccination (breakthrough group), and the remaining 77 (57%) did not experience Omicron infection (non-breakthrough group). There was no significant different in 'peak' SARS-CoV-2 S1-specific IgG level between breakthrough group (median 4484.4 IU/mL) and non-breakthrough group (median 4194.9 IU/mL, p value=0.39). In addition, there was no significant difference in 'peak' neutralizing antibody titer (ID50) against Omicron between breakthrough group (median 2597.9) and non-breakthrough group (median 2597.9, p value=0.86). (Table Presented) Serum samples were obtained from 134 healthcare workers 2 weeks after booster vaccination. Samples were analysed for SARS-CoV-2 S1-specific IgG antibody titers using enzyme-linked immunosorbent assay (ELISA) and plasma levels of live-virus neutralizing antibodies using a microneutralization assay with SARS-CoV-2 omicron variants. There was no significant difference in 'peak' SARS-CoV-2 S1-specific IgG level (A) and 'peak' neutralizing antibody titer (ID50) against Omicron (B) between breakthrough group and non-breakthrough group. Conclusion. We did not find the correlation of neutralizing antibody titers about several months before infection with breakthrough Omicron infections. These data suggest rapidlywaning neutralizing titers to protect mild illnesses or asymptomaticOmicron infections several months after current booster COVID-19 vaccination in HCWs.
ABSTRACT
Background. Pregnant women with SARS-CoV-2 infection are known to have a poor prognosis. In addition, the previous meta-analysis revealed that SARS-CoV-2 infection in neonates born from pregnant women with SARS-CoV-2 infection is about 2%. However, there are limited data on the clinical characteristics of pregnant women with SARS-CoV-2 infection and their neonates and the vertical transmission rate in South Korea. Methods. Pregnant women confirmed as SARS-CoV-2 infection were retrospectively reviewed in Asan Medical Center from September 1 2020 to April 26 2022. All neonates from SARS-CoV-2-infected women underwent SARS-CoV-2 PCR within 24 hours after the birth and 48-hour interval if he or she stayed in the hospital. Results. A total of 60 pregnant women gave birth by cesarean section (n=40, 67%) or vaginal delivery (n=20, 33%). Among them, three women gave birth to twins (63 neonates). Delivery was carried out at the average gestational age of 268 days (+/- 14.0), and 9 patients (15%) had underlying diseases. Of these 60 patients, 11 (18%) received COVID-19 vaccination. Pneumonia was confirmed by chest radiograph in 7 patients (12%), and 2 patient (3%) required supplemental oxygen therapy who eventually recovered. The mean weight of 63 newborns was 3137 g (+/- 558), and 8 neonate (13%) was a low-birth weight (< 2500 g), and 12 neonate (19%) was premature (< gestational age 37 weeks). Apgar score was 8.1 points (+/- 1.2) at 1 minute and 9.1 points (+/- 0.8) at 5 minutes. Five neonates (8%) required mechanical ventilation, who eventually recovered. All 63 neonates revealed negative SARS-CoV-2 PCR results with 24 hours after the birth. After 48 hours, 45 newborns exhibited negative SARS-CoV-2 PCR results. So, there was no vertical transmission among 63 neonates (0%, 95% CI 0-6). Conclusion. Our experiences about pregnant women with SARS-CoV-2 infection revealed that obstetric outcomes were favorable and the vertical transmission risk was low. Balancing risks about the infection control of pregnant women and their neonates during the COVID-19 pandemic are needed.
ABSTRACT
Background. Centers for Disease Control and Prevention (CDC) recommends 5 to 20 days of isolation for COVID-19 patients depending on symptom duration and severity regardless of genomic PCR results or vaccination history. However, in real clinical practice, more individualized approach is required. We thus developed clinical scoring system to predict viable viral shedding in a given patient by using various factors affecting viable viral shedding. Methods. We prospectively enrolled adult patients with SARS-CoV-2 infection admitted to tertiary hospital and day care center between February 2020 and January 2022. The daily dense respiratory sampling (i.e. saliva, sputum, or nasopharyngeal swabs) during the hospital and day care center stay were obtained. Genomic RNA viral load and viral culture were performed for these samples. Clinical predictors of negative viral culture results were identified using survival analysis and multivariable analysis. Results. A total of 612 samples from 121 patients of varying degrees of severity were obtained. Of these, 494 (81%) samples were saliva, 63 (10%) were nasopharyngeal swab, and the remaining 55 (9%) were sputum. Of these 612 specimens, 154 (25%) samples revealed positive viral culture results. Univariate and multivariable Cox's time varying proportional hazard model revealed that symptom onset day, viral copy number, disease severity, organ transplant recipient, gender, and vaccination status were independently associated with viral culture results. We thus developed the 5-factor model from -3 to 3 points: viral copy number (-3 to 3 points depending on copy number), disease severity (1 point to moderate to critical diseases), organ transplant recipient (2 points), gender (-1 points to male), and vaccination status (-2 points to fully vaccinated status). The predictive culture-negative rates were calculated through the symptom onset day and the score of the day the sample was collected. Conclusion. Our clinical scoring system can provide objective probability of negative culture results in a given COVID-19 patient with genomic viral load, and appears to be useful to decide de-isolation policy depending on individualized factors associated with viable viral shedding beyond simple symptom-based isolation strategy by CDC.
ABSTRACT
Background. Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) variant strain B.1.1.529 (omicron) has been less virulent than SARS-CoV-2 B.1.617.2 variant (delta), but there are limited data on the comparison of the cause of death between delta variant and omicron variant infections. We thus compared the causes of death in COVID-19 patients with the delta variant and omicron variant. Methods. We retrospectively reviewed the medical records of adult patients with COVID-19 who were admitted at Asan Medical Center, Seoul, South Korea, between July 2021 and March 2022. We divided into delta-variant dominant period (from July 2021 to December 2021) and omicron-dominant period (from February 2022 to March 2022) with the exclusion of January 2022 because this period was overlapping of delta and omicron variant. The causes of death were classified into COVID-19-associated pneumonia, other causes, and indeterminate cause. Results. A total of 654 patients with COVID-19 were admitted and 42 (6.4%) died during the omicron dominant period (between February and March 2022), while a total of 366 patients with COVID-19 were hospitalized and 42 (11.5%) died during the delta dominant period (between July and December 2021). The primary cause of death was COVID-19-associated pneumonia in 64% (27/42) during the omicron era whereas that was COVID-19-associated pneumonia in 88% (37/42) during the delta era (p value=0.01) (Table 1). Conclusion. We found that about two thirds of patients with omicron variant infection died due to COVID-19, while the majority of patients with delta variant infection died due to COVID-19.
ABSTRACT
Background. Understanding the rate and composition of bacterial co-infection is important to determine antibiotic therapy in SARS-CoV-2 infection, but those vary according to healthcare settings and regional differences. We evaluated the rate of bacterial co-infection in hospitalized patients with COVID-19 in a single tertiary hospital in South Korea. Methods. In this retrospective study, all the adult patients with COVID-19 hospitalized between Feb 2020 and Dec 2021 were included. Bacterial co-infection rate was assessed by results of sputum cultures, blood cultures, pneumococcal urinary antigen, Legionella urinary antigen, sputum Legionella pneumophilia PCR, and sputum multiplex PCR for Mycoplasma pneumoniae and Chlamydia pneumoniae. Characteristics and outcomes of patients were evaluated according to antibiotics exposure prior to hospitalization. Results. Of 367 adult patients, 300 (81.7%) patients having sputum culture results were included in the analysis. Of these, 127 (42.3%) had a history of antibiotic exposure within 1 month before hospitalization. The coinfection rate within 48 hours of hospitalization was confirmed in 8.3% (25/300): 6.4% (11/163) of patients without prior antibiotic exposure and 11% (14/127) of patients with prior antibiotic exposure. In the group without prior antibiotic exposure, pathogens responsible for community-onset infections were isolated, whereas nosocomial pathogens were predominantly isolated in the antibiotic-exposed group. Empirical antibiotics were used in 144 (66%) of 275 patients without positive results for microbiological tests. Empirical antibiotic use in patients without positive results for microbiological tests was not significantly associated with 30-day mortality or in-hospital mortality after adjusting covariates including age, sex, comorbidity, anti-inflammatory treatment, and COVID-19 severity. Conclusion. In this study with a high rate of microbiological testing, bacterial coinfection was not frequent, and the results varied depended on previous exposure to antibiotics. Given the rarity of bacterial co-infection and the lack of potential benefits of empirical antibiotic therapy, the antibiotic use in patients with COVID-19 should be restricted as an important target of antibiotic stewardship. (Table Presented).
ABSTRACT
Purpose: Understanding risk factors for impaired vaccine responses can guide strategies for testing, additional dose recommendations, and vaccine schedules to provide improved protection in solid organ transplant recipients (SOTRs). Our purpose was to use machine learning to characterize risk factors and create a prediction model for seroconversion after 2-dose mRNA SARS-CoV-2 vaccination. Method(s): Using our national observational cohort of 1031 SOTRs we created a machine learning model using gradient boosting to explore, rank, and quantify the association of 19 clinical factors with antibody responses to 2-dose mRNA vaccination. Gradient boosting is a general-purpose machine learning algorithm that generates a sequence of parsimonious prediction models based on the residual error of the previous models. We measured the area under the receiver operating characteristic curve (AUROC) via a 10-fold cross validation to evaluate the model's performance. Finally, we evaluated the prediction performance of the models in discrimination and calibration with an external cohort of 512 SOTRs from Houston Methodist. Result(s): Mycophenolate mofetil (MMF) use, shorter time since transplant, and older age were the strongest predictors of seronegativity, collectively contributing to 76% of the model's prediction performance (Figure 1). Other clinical factors, including organ type, vaccine type, sex, race, and other immunosuppression medications, showed weaker associations with seronegativity. Longer time since transplant was associated with higher odds of seropositivity, especially during the first 5 years post-transplant (Figure 2a). Older age among those <65 years old (Figure 2b) and MMF (Figure 2c) were associated with lower odds of seropositivity. The model had moderate prediction performance, with an AUROC of 0.79 (our cohort) and 0.67 (Houston Methodist cohort). Conclusion(s): Our machine learning model allows us to identify SOTRs at highest risk of suboptimal immunogenic response to vaccination, highlighting opportunities for improving protection from COVID-19 including more targeted vaccination strategies. (Figure Presented).
ABSTRACT
Purpose: To compare antibody response to a third dose (D3) of SARS-CoV-2 vaccine in solid organ transplant recipients (SOTRs) with negative or low-positive antibody levels after 2-dose mRNA vaccination across D3 platforms. Method(s): From our observational study, 532 SOTRs who developed suboptimal antibody responses to 2-dose mRNA vaccination (Roche<50 U/mL or EUROIMMUN <1.1 AU) were selected. Belatacept recipients and persons with any COVID-19 diagnosis were excluded. We compared post-D3 antibody levels among SOTRs who received an mRNA vaccine for D3 (n=487) versus Ad.26.COV2.S for D3 (n=45). Poisson regression with robust standard error was used to study the association between vaccine platform and seroconversion, adjusting for immunosuppression, age, time since transplant, and liver transplant status. Result(s): Pre-D3, 342 SOTRs (64%) were seronegative, of whom 107 (31%) developed high-positive antibody levels post-D3. In contrast, of the 190 (36%) with low-positive pre-D3 antibody levels, 172 (91%) were high-positive post-D3 (Figure 1). Among SOTRs seronegative pre-D3, 1.8x more Ad.26.COV2.S D3 recipients seroconverted compared to mRNA D3 recipients (49.7% vs 27.8%, Fisher's exact=0.014) (Figure 2). Among the pre-D3 seronegative group, there was a 2x higher chance of developing high-positive post-D3 levels with Ad.26.COV2.S compared to mRNA D3 (IRR =1.42.02.9, p<0.001). This was despite the Ad.26. COV2.S D3 group having fewer younger patients and liver transplant recipients, factors that are associated with higher odds of positive antibody response. 165 SOTRs (31%) remained seronegative after D3 (22% of Ad.26.COV2.S recipients vs 32% of mRNA recipients). Conclusion(s): Heterologous boosting with Ad.26.COV2.S may be a promising vaccination option for SOTRs with poor response to the 2-dose mRNA series, particularly among those who are seronegative. (Table Presented).
ABSTRACT
SESSION TITLE: Issues After COVID-19 Vaccination Case Posters SESSION TYPE: Case Report Posters PRESENTED ON: 10/19/2022 12:45 pm - 01:45 pm INTRODUCTION: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder that can lead to thrombosis, hemolytic anemia and leukemia. Though there are documented relationships between autoimmune hemolytic anemia (AIHA) and COVID-19 infection, this is the first to highlight aa potential association between PNH exacerbations and COVID vaccinations. CASE PRESENTATION: A 38 year-old female with a history of chronic paroxysmal nocturnal hemoglobinuria (PNH) currently on maintenance ravculizumab therapy presented with 3 days of generalized fatigue, chills, and worsening scleral icterus. She reports being unable to move out of the bed with concomitant somnolence. Of note, she received her second dose of the Moderna COVID-19 vaccine 2 days prior to symptom onset and not had any similar symptoms prior to this episode. Patient was hemodynamically stable on admission and afebrile. Physical exam revealed generalized lethargy/weakness and jaundice. Chest x-ray did not demonstrate any evidence of infection or pleural effusions. Initial complete blood count showed a hemoglobin of 5.9 g/dL, compared to her baseline of 9 without any evidence of bleeding. Absolute reticulocyte and bilirubin levels were elevated to 295.2 x 109 and 4.7 mg/dL respectively with a haptoglobin of <20 mg/dL. She received a total of 3 units of packed red-blood cells with subsequent stable hemoglobin levels and did not require emergent use of glucocorticoids or plasma exchange. Her lethargy improved slowly, and within a week, she returned back to her baseline functional status. She was ultimately stable and discharged for follow up with her hematologist without any complications. DISCUSSION: Though the sequelae of COVID-19 infections and associated hematologic diseases have been extensively established, the pathogenesis of COVID-19 vaccinations associated exacerbations remain unclear. Given the timing of the onset of our patient's symptoms, it is highly suggestive that her second COVID-19 vaccination was the inciting factor for her acute hemolytic anemia. It is crucial to be cognizant of the potential hematologic side effects in individuals with rare auto-immune disorders such as PNH and take into consideration the timing of vaccination or booster administrations. CONCLUSIONS: While COVID-19 vaccination benefit most likely outweighs the risks for this specific patient population, our case raises the question about the need for extra precautions in patients with known PNH associated AIHA including the timing of PNH treatment before receiving the vaccination. Reference #1: Algassim AA, Elghazaly AA, Alnahdi AS, Mohammed-Rahim OM, Alanazi AG, Aldhuwayhi NA, Alanazi MM, Almutairi MF, Aldeailej IM, Kamli NA, Aljurf MD. Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection. Annals of Hematology. 2021 Jan;100(1):37-43. DISCLOSURES: No relevant relationships by Suhwoo Bae No relevant relationships by Edward Bae No relevant relationships by Joseph You
ABSTRACT
Background: The coronavirus disease 2019 (COVID-19) pandemic has affected not only the control and management of infectious diseases, but also those of other diseases by deteriorating the general healthcare systems worldwide. In accordance with the suggestion by the WHO for postponement of non-urgent procedures, diagnosis and treatment strategies for the patients with malignancy have been changed. The aim of this study was to investigate the impact of COVID-19 pandemic on primary colorectal cancer (CRC) from multi-institutions in Korea. Methods: Medical records of consecutive patients with CRC between March 2019 and February 2021 in six university hospitals were reviewed. Recurrent diseases, admission for management of complications or enterostomy repair, and other pathologies than adenocarcinoma were excluded. Baseline characteristics and perioperative outcomes were compared after a cohort was divided into the two groups: before and after around March 2020, when the COVID-19 test has been mandatory for all admitted patients in most institutions. Treatment characteristics and pathologic outcomes were also compared between the two groups. Results: A total of 3895 patients with CRC admitted during the study period. After 454 patients were excluded, 1820 and 1621 patients were assigned to the pre-pandemic and pandemic groups. The proportion of patients who could not receive curative or palliative surgery for stage IV diseases was not different (88 vs. 91, P>0.999), and 3262 patients underwent surgery for primary CRC. Among them, the pandemic group showed more previous abdominal surgery (21.2% vs. 15.4%, P<0.001), higher preoperative CEA level (46.7 vs. 16.0 ng/mL, P=0.021), and less stent insertion for obstructive lesion (33% vs. 46.4%, P=0.043). There was no difference in sex, age, the ASA grade, and tumor location between the groups. Perioperative outcomes including operation time, operation method, operation type, and postoperative complication rates were not different, whereas more stoma formation was performed in the pandemic group (15.3% vs. 12.4%, P=0.024). Pathologic outcomes including TNM stage, tumor diameter, harvested lymph nodes, and lymphovascular invasion were not different. However, the pandemic group showed higher tendency of lymph node metastasis (44% vs. 40.6%, P=0.070) and more adjuvant chemotherapy (26.4% vs. 20.1%, P<0.001). Conclusions: Although a few factors indicated more advanced CRC, clinical features and perioperative outcomes of the patients in COVID-19 pandemic seemed not to be aggravated in Korea. The national healthcare system which was not shut down in the pandemic, and relatively small number of COVID-19 prevalence might influence these results, although patients' access and medical checkup seemed to decrease slightly. The cause and effect of decreased medical access would be clarified by long-term follow up data.
ABSTRACT
Deep learning based models on the edge devices have received considerable attention as a promising means to handle a variety of AI applications. However, deploying the deep learning models in the production environment with efficient inference on the edge devices is still a challenging task due to computation and memory constraints. This paper proposes a framework for the service robot named GuardBot powered by Jetson Xavier NX and presents a real-world case study of deploying the optimized face mask recognition application with real-time inference on the edge device. It assists the robot to detect whether people are wearing a mask to guard against COVID-19 and gives a polite voice reminder to wear the mask. Our framework contains dual-stage architecture based on convolutional neural networks with three main modules that employ (1) MTCNN for face detection, (2) our proposed CNN model and seven transfer learning based custom models which are Inception-v3, VGG16, denseNet121, resNet50, NASNetMobile, XceptionNet, MobileNet-v2 for face mask classification, (3) TensorRT for optimization of all the models to speedup inference on the Jetson Xavier NX. Our study carries out several analysis based on the models' performance in terms of their frames per second, execution time and images per second. It also evaluates the accuracy, precision, recall & F1-score and makes the comparison of all models before and after optimization with a main focus on high throughput and low latency. Finally, the framework is deployed on a mobile robot to perform experiments in both outdoor and multi-floor indoor environments with patrolling and non-patrolling modes. Compared to other state-of-the-art models, our proposed CNN model for face mask recognition based on the classification obtains 94.5%, 95.9% and 94.28% accuracy on training, validation and testing datasets respectively which is better than MobileNet-v2, Xception and InceptionNet-v3 while it achieves highest throughput and lowest latency than all other models after optimization at different precision levels.
ABSTRACT
Background Although the number of patients presenting with non-ST elevation myocardial infarction (NSTEMI) has drastically reduced in the coronavirus-19 pandemic era, increased mortality was reported. A plausible explanation for increased mortality was suggested as the delay of arrival at the hospital due to patients’ reticence of their symptoms. However, evidence to support the suggested explanation is lacking. Methods From the nationwide prospective registry, we evaluated 6,544 patients with NSTEMI. Study patients were categorized into two groups according to their symptom-to-door (StD) time (<24 h or ≥24 h). The primary outcome was 3-year all-cause mortality, and the secondary outcome was 3-year composite of all-cause mortality, recurrent MI, and hospitalization for heart failure. Results Overall, 27.9% patients were classified into the StD time ≥24 h group. The StD time ≥24 h group had higher all-cause mortality (17.0% vs. 10.5%, p<0.001) and incidence of secondary outcome (23.3% vs. 15.7%, p<0.001) than the StD time <24 h group. In the multivariable analysis, independent predictors of delayed arrival at the hospital were the elderly, female, non-specific symptoms such as atypical chest pain or dyspnea, diabetes, and no use of emergency medical services. Conclusion Delayed arrival (StD time ≥24 h) is associated with an increased risk of 3-year all-cause mortality and composite outcomes in patients with NSTEMI. [Formula presented]
ABSTRACT
COVID-19 might not have severely threatened young children's physical health;however, it has had profound impacts on their sound development and mental health that could have long-lasting effects on their lives. It is not easy to foresee when this crisis will be over;yet young children’s development and learning cannot be stopped. Therefore, efforts to support young children, considering the impacts of the COVID-19 crisis, must be made immediately. The purposes of this study are to review the existing literature on the effects of the pandemic on young children’s healthy development, and to revisit the value of young children’s play in the context of the COVID-19 crisis. This article begins with general directions for supporting young children during and after the crisis, followed by three sections including (1) impacts of the COVID-19 crisis on young children;(2) mental health and development of young children;and (3) play for young children during and after pandemic. Conclusions and suggestions for future research are provided. © 2022 by THE PACIFIC